No headlines found.
SeaStar Medical to Present at the HC Wainwright 28th Annual Global Investment Conference
Globe Newswire (Thu, 10-Sep 8:35 AM ET)
SeaStar Medical Reports Second Quarter 2026 Financial Results and Provides Business Updates
Globe Newswire (Wed, 12-Aug 4:05 PM ET)
SeaStar Medical to Report Second Quarter Financial Results on August 12, 2026
Globe Newswire (Thu, 6-Aug 8:35 AM ET)
Globe Newswire (Tue, 14-Jul 8:34 AM ET)
SeaStar Medical Announces New ICD-10-PCS Codes for Its SCD Therapy for Acute Kidney Injury
Globe Newswire (Tue, 23-Jun 8:25 AM ET)
SeaStar Medical to Present at Upcoming Investor Summit Conference
Globe Newswire (Mon, 22-Jun 8:45 AM ET)
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.
Seastar Medical Holding trades on the NASDAQ stock market under the symbol ICU.
As of September 14, 2026, ICU stock price climbed to $3.07 with 9,920 million shares trading.
ICU has a beta of 3.26, meaning it tends to be more sensitive to market movements. ICU has a correlation of 0.14 to the broad based SPY ETF.
ICU has a market cap of $13.53 million. This is considered a Sub-Micro Cap stock.
Last quarter Seastar Medical Holding reported $615,000 in Revenue and -$.91 earnings per share. This beat revenue expectation by $125,800 and exceeded earnings estimates by $.05.
In the last 3 years, ICU traded as high as $429.23 and as low as $2.07.
The top ETF exchange traded funds that ICU belongs to (by Net Assets): VXF, DFAC.
ICU has underperformed the market in the last year with a price return of -64.7% while the SPY ETF gained +16.9%. However, in the short term, ICU had mixed performance relative to the market. It has outperformed in the last 3 months, returning +3.0% vs +2.8% return in SPY. But in the last 2 weeks, ICU shares have been beat by the market, returning -1.9% compared to an SPY return of -0.8%.
ICU support price is $2.90 and resistance is $3.16 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ICU shares will trade within this expected range on the day.